News | August 11, 2011

Science, Government, Industry Converge in National Call to Action on Lung Cancer

August 11, 2011 -- The New England Journal of Medicine's recent publication of the landmark National Lung Screening Trial (NLST), along with two congressional initiatives and an industry report, herald a much brighter future for lung cancer patients.

Forty-three million Americans suffer from a chronic pulmonary disease, such as lung cancer, chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Pulmonary diseases account for three out of the top five disease states with the highest incidence of mortality. Lung cancer is the deadliest of all cancers, causing nearly 30 percent of all cancer-related deaths, killing over 200,000 Americans annually. In 2009, the Lung Cancer Alliance confirmed that 70,490 women perished from lung cancer, more than all other female-related cancers (breast, cervical, uterine, and ovarian) combined.

Larry Gerrans, CEO and co-founder of Sausalito, Calif.-based Sanovas, a manufacturer of therapy-enabling technologies for the treatment of pulmonary disease and lung cancer, said, "As we have seen with other chronic diseases, early detection has proved to save lives and relieve the emotional and financial hardship these diseases have on families and on the health care system. The NLST promises new hope for patients who otherwise would not know that lung cancer has taken hold of them."

Published August 4, the reduced lung-cancer mortality with low-dose computed tomographic (CT) screening study found a 24.2 percent increase in the detection of lung cancer using low-dose CT over chest X-ray alone. The study, which enrolled 53,454 persons at high risk for lung cancer at 33 United States medical centers, also found a 20 percent reduction in mortality from lung cancer in patients who were screened with a low-dose CT.

"This is the first time that we have seen clear evidence of a significant reduction in lung cancer mortality with a screening test in a randomized controlled trial. The fact that low-dose helical CT provides a decided benefit is a result that will have implications for the screening and management of lung cancer for many years to come," says Christine Berg, M.D., the National Cancer Institute project officer for the study.

Congress, in its effort to reduce the cost burden of lung cancer on the gross domestic product (GDP) of the country, has architected two legislative initiatives, in response to the national call to action on lung cancer. The bi-partisan, bi-cameral Lung Cancer Mortality Reduction Act, originally sponsored by Diane Feinstein (D-Calif.), was recently reintroduced in the 112th Congress. The Senate Bill (S.752) and its House counterpart (HR 1394) would establish the first-ever multi-agency comprehensive program targeted at lung cancer.

The "Medicare Lung Cancer Early Detection Promotion Act of 2011" seeks to amend title XVIII of the Social Security Act to provide reimbursement for chest radiography services that use computer-aided detection (CAD) technology for the purpose of
early detection of lung cancer.

Markets and Markets (M&M), a global market research and consulting company based in the United States, declared in its July 2011 analysis that "the market for lung cancer surgeries alone was valued at $36 Billion in 2010 and expected to grow to $45 Billion by 2015."

For more information:

Related Content

Coreline Soft Introduces AI Lung Segmentation Solution at RSNA 2018
News | Lung Cancer | December 10, 2018
December 10, 2018 — Korean image software company Coreline Soft Co. Ltd.
FDA Approves New Features for Planmed Verity Cone Beam CT Scanner
Technology | Computed Tomography (CT) | December 07, 2018
The U.S. Food and Drug Administration (FDA) issued an approval letter for the new features and intended uses of the...
YITU Releases AI-Based Cancer Screening Solutions at RSNA 2018
News | Artificial Intelligence | December 06, 2018
Chinese artificial intelligence (AI) healthcare company YITU healthcare released two brand-new products, Intelligent...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
GE Healthcare Unveils New Applications and Smart Devices Built on Edison Platform
Technology | Artificial Intelligence | December 05, 2018
GE Healthcare recently announced new applications and smart devices built on Edison – a platform that helps accelerate...
Infervision Introduces AI Capabilities for Chest CT Reading
Technology | Computer-Aided Detection Software | November 30, 2018
Big data and artificial intelligence (AI) company Infervision announced the launch of InferRead CT Chest, a new product...
NeuroLogica and MaxQ AI Announce Distribution Agreement
News | Stroke | November 30, 2018
Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement...
Videos | Advanced Visualization | November 30, 2018
This is an example of the FDA-cleared OpenSight augmented reality (AR) system for surgical planning from NovaRad at t
Vital Showcases Enterprise Imaging Advances at RSNA 2018

Global Illumination from Vital Images

News | Enterprise Imaging | November 28, 2018
Vital, a Canon Group company, will highlight the latest additions to its enterprise imaging portfolio at the 2018...